001     282543
005     20251201102734.0
024 7 _ |a 10.1093/nop/npaf101
|2 doi
024 7 _ |a 2054-2577
|2 ISSN
024 7 _ |a 2054-2585
|2 ISSN
037 _ _ |a DZNE-2025-01306
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Zeyen, Thomas
|0 0009-0006-2919-8622
|b 0
245 _ _ |a Proof of concept: Portable ultra-low-field MRI for the assessment of brain tumors
260 _ _ |a Oxford
|c 2025
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1764581171_18439
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a BackgroundHigh-field (HF) MRI is a standard diagnostic tool for brain cancer, but its high cost and technical demands limit accessibility in low- and middle-income countries. Recent advancements in ultra-low field (ULF) MRI technology, including the development of portable scanners, offer a promising solution to these challenges. This study evaluates the diagnostic capabilities of ULF-MRI in detecting brain cancer and compares radiological evaluation using ULF- with HF-MRI.MethodsConsecutive patients with suspected or confirmed brain tumors undergoing routine 3T HF-MRI at the University Hospital Bonn were recruited for this study and underwent ULF-MRI. Eligible patients were at least 18 years old and had MRI-abnormalities in the HF-MRI. The 0.064 Tesla Swoop portable MR Imaging System was utilized. HF-MRI and ULF-MRI scans were independently evaluated by two experienced neuroradiologists and results were compared.ResultsThirteen patients were recruited, of whom 11 (85%) were diagnosed with brain tumors. In 11/11 (100%) patients with brain tumors, ULF-MRI identified tumor lesions corresponding to the findings of HF-MRI. In 7/11 (63.6%) identification of all tumor lesions could be achieved. Three of four further relevant imaging findings in HF-MRI (e.g. acute hydrocephalus or concomitant ischemia) were also found in in ULF-MRI.ConclusionThis single-center study demonstrates that ULF-MRI is a practical tool in neuro-oncology, which may particularly be helpful in resource-limited settings. Further research is required to define the role of ULF-MRI alongside existing imaging modalities for brain cancer diagnosis and management.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
700 1 _ |a Sabir, Hemmen
|0 P:(DE-2719)9000732
|b 1
|u dzne
700 1 _ |a Bauer, Tobias
|0 P:(DE-2719)9002598
|b 2
700 1 _ |a Henke, Oliver
|b 3
700 1 _ |a Lehnen, Nils
|b 4
700 1 _ |a Zidan, Mousa
|b 5
700 1 _ |a Olbrich, Simon
|b 6
700 1 _ |a Lange, Annalena
|b 7
700 1 _ |a Bisten, Justus
|b 8
700 1 _ |a Groteklaes, Anne
|b 9
700 1 _ |a Faber, Jennifer
|0 P:(DE-2719)2811327
|b 10
|u dzne
700 1 _ |a Röver, Lea
|b 11
700 1 _ |a Schäfer, Niklas
|b 12
700 1 _ |a Weller, Johannes
|0 0000-0001-5818-5392
|b 13
700 1 _ |a Bruchhausen, Walter
|b 14
700 1 _ |a Radbruch, Alexander
|0 P:(DE-2719)9001861
|b 15
|u dzne
700 1 _ |a Herrlinger, Ulrich
|b 16
700 1 _ |a Rüber, Theodor
|0 0000-0002-6180-7671
|b 17
773 _ _ |a 10.1093/nop/npaf101
|g p. npaf101
|0 PERI:(DE-600)2768945-1
|p npaf101
|t Neuro-oncology practice
|v AOP
|y 2025
|x 2054-2577
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9000732
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9002598
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2811327
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)9001861
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURO-ONCOL PRACT : 2022
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-01
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-01
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-01
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-01
920 1 _ |0 I:(DE-2719)5000032
|k AG Sabir
|l Neonatal Neuroscience
|x 0
920 1 _ |0 I:(DE-2719)5000075
|k AG Radbruch
|l Clinical Neuroimaging
|x 1
920 1 _ |0 I:(DE-2719)1011401
|k Clinical Research Platform (CRP)
|l Clinical Research Platform (CRP)
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)5000032
980 _ _ |a I:(DE-2719)5000075
980 _ _ |a I:(DE-2719)1011401
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21